melanoma - Cleveland Clinic

Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}}
Now: 1771013570340
Cache Key: cqdTagPageBySlug:melanoma
fetchCache[cqdTagPageBySlug:melanoma].expirationTime: falsey
fetchCache[cqdTagPageBySlug:melanoma]. seconds remaining: falsey
All fetchCache expiration times:
-- Key: cqdNotFoundPage, seconds remaining: -122414
-- Key: cqdTagPageBySlug:bela-anand-apte, seconds remaining: -694769
-- Key: cqdPostsByTag:cqd-migrated-tag-1216,1,10, seconds remaining: -694680
-- Key: cqdTagPageBySlug:rebecca-cesa, seconds remaining: -122414
-- Key: cqdPostsByTag:cqd-migrated-tag-2771,1,10, seconds remaining: -122343
conditions:
-- false,
-- NA,
-- NA,
-- NA
-- false
Cache miss for key cqdTagPageBySlug:melanoma - retrieving from Sanity
CCCache.dataFetchCount: 44
Cache cleanup seconds remaining: 30000

Tag: melanoma

Case Study: An Immunotherapy-First Approach for a 79-Year-Old With Stage IIB Melanoma

Study Reveals New Clues Into Childhood Cancer Survivors’ Increased Risk of Melanoma

Iris Freckle, Mole or Melanoma? How to Tell the Difference

Inherited Risk May Play a Larger Role in Melanoma Than Previously Believed

Novel Therapeutics Clinic Offers Access to Early-Phase Trials for Solid Tumors

Questions Remain about When to Employ Immunotherapy for Resected High-Risk Melanoma

The Changing Treatment Landscape for Patients with Metastatic Melanoma

New Model Based on CD8 T Cells May Distinguish ICI Responders from Non-Responders in Melanoma

Cellular Therapy Across Cleveland Clinic

Adjuvant Pembrolizumab Improves Relapse-Free Survival in Patients with High-Risk Resected Melanoma